First-in-Class PS-Targeting Monoclonal Antibody for Viral Infections

Bavituximab is the first in a new class of patented antibodies that target and bind to the cellular membrane component phosphatidylserine (PS). PS is a highly immunosuppressive molecule usually located inside cells, but which becomes exposed on the outside of the membranes of certain viruses and virally infected cells, creating a potential target for antiviral therapy.

Phase II Bavituximab HCV Clinical Trial

Patient enrollment was completed in a randomized Phase II clinical trial in patients with previously untreated genotype-1 hepatitis C virus (HCV) infection.  This open-label trial was designed to determine the early virologic response (EVR) rate of patients after 12 weeks of therapy with bavituximab in combination with the antiviral drug ribavirin versus pegylated interferon alpha-2a and ribavirin. Data from the study reported in December 2011, showed antiviral activity and a positive safety profile at both bavituximab doses evaluated, supporting further dosing combination studies. Bavituximab has been generally safe and well tolerated in three prior Phase I HCV trials.